{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=GlaxoSmithKline",
    "query": {
      "sponsor": "GlaxoSmithKline",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 2128,
    "total_pages": 213,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=4&sponsor=GlaxoSmithKline&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=GlaxoSmithKline&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T02:16:18.573Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00264615",
      "title": "Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "lamotrigine extended-release",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2005-10",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-10-12T02:16:18.573Z",
      "location_count": 12,
      "location_summary": "Anniston, Alabama • Sun City, Arizona • Lexington, Kentucky + 8 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00264615"
    },
    {
      "nct_id": "NCT00951015",
      "title": "A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK1349572",
          "type": "DRUG"
        },
        {
          "name": "efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2009-07-30",
      "completion_date": "2016-12-22",
      "has_results": true,
      "last_update_posted_date": "2018-01-16",
      "last_synced_at": "2026-10-12T02:16:18.573Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Long Beach, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00951015"
    },
    {
      "nct_id": "NCT01283789",
      "title": "Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Lapatinib and RAD-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 23,
      "start_date": "2011-02",
      "completion_date": "2017-04",
      "has_results": false,
      "last_update_posted_date": "2017-02-08",
      "last_synced_at": "2026-10-12T02:16:18.573Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01283789"
    },
    {
      "nct_id": "NCT00048360",
      "title": "Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Disorder"
      ],
      "interventions": [
        {
          "name": "Extended-release bupropion hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 162,
      "start_date": "2002-10",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2013-02-12",
      "last_synced_at": "2026-10-12T02:16:18.573Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Chula Vista, California • Lafayette, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048360"
    },
    {
      "nct_id": "NCT00615524",
      "title": "Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-receptor Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "exemestane and pazopanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2008-04",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2018-01-12",
      "last_synced_at": "2026-10-12T02:16:18.573Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00615524"
    },
    {
      "nct_id": "NCT07358546",
      "title": "A Study of Efimosfermin Alfa in Adults With Hepatic Impairment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Efimosfermin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 32,
      "start_date": "2026-03-13",
      "completion_date": "2027-10-13",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-12T02:16:18.573Z",
      "location_count": 3,
      "location_summary": "Rialto, California • Tampa, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07358546"
    },
    {
      "nct_id": "NCT01657877",
      "title": "Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Caries"
      ],
      "interventions": [
        {
          "name": "Calcium sodium phosphosilicate",
          "type": "DRUG"
        },
        {
          "name": "Sodium monoflurophosphate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 100,
      "start_date": "2012-05",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-10-01",
      "last_synced_at": "2026-10-12T02:16:18.573Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01657877"
    },
    {
      "nct_id": "NCT00839527",
      "title": "A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "placebo to match albiglutide",
          "type": "DRUG"
        },
        {
          "name": "albiglutide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "metformin",
          "type": "DRUG"
        },
        {
          "name": "glimepiride",
          "type": "DRUG"
        },
        {
          "name": "pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "placebo to match pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 685,
      "start_date": "2009-02",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-10-12T02:16:18.573Z",
      "location_count": 321,
      "location_summary": "Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 257 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00839527"
    },
    {
      "nct_id": "NCT02741557",
      "title": "Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DTG",
          "type": "DRUG"
        },
        {
          "name": "RPV",
          "type": "DRUG"
        },
        {
          "name": "DTG/RPV FDC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 118,
      "start_date": "2016-05-11",
      "completion_date": "2016-10-24",
      "has_results": false,
      "last_update_posted_date": "2019-07-15",
      "last_synced_at": "2026-10-12T02:16:18.573Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02741557"
    },
    {
      "nct_id": "NCT02281370",
      "title": "Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Purpura, Thrombocytopenic, Idiopathic"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 39,
      "start_date": "2014-11-05",
      "completion_date": "2014-12-24",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-10-12T02:16:18.573Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02281370"
    }
  ]
}